Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Citizen Meds vs Omada Health

Citizen Meds
Graded #254

Higher grade

vs+8.100000000000001
Omada Health
Graded #436

Lower grade

The verdict

Citizen Meds takes it — 63.7/100 to 55.6/100.

Citizen Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Citizen Meds is a GLP-1/weight-loss injection provider offering semaglutide.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCitizen Meds +25
70
45
Dose & formulationCitizen Meds +14
54
40
Clinical oversightCitizen Meds +2
79
77
Labs & monitoringOmada Health +9
52
61
FulfillmentEven
62
62
Contract termsEven
55
55
Citizen Meds · left barOmada Health · right bar

The numbers

MetricCitizen MedsOmada Health
WeighScore63.7/10055.6/100
GradeCC
Scorecard rank#254#436
Semaglutide$125/mo (0.25 mg dose, compounded)Not disclosed
Tirzepatide$185/mo (2.5 mg dose, first-month rate, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Citizen Meds

Graded #254 · C

Strengths

  • Semaglutide confirmed from product listings
  • New-patient discount available (code NEWPATIENT10)

Where it loses points

  • No visible LegitScript or PCAB accreditation
  • State availability not disclosed
  • About page returns a 404
  • Limited overall transparency
Omada Health

Graded #436 · C

Strengths

  • Added GLP-1 prescribing and medication management in late 2025
  • Clinicians trained in obesity care, available in all 50 states
  • Behavioral support wrapped before, during and after treatment
  • GLP-1 Flex Care adds a cash-pay medication pathway in 2026
  • Publicly traded, evidence-based virtual care platform

Where it loses points

  • Core program distributed via employers and health plans, limited cash-pay
  • GLP-1 prescribing is a recent addition still scaling
  • GLP-1 Flex Care only rolling out to employers later in 2026
  • No transparent published price for the core member program

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard